Lisa Holper1,2, Martin J Lan1, Patrick J Brown3, Elizabeth M Sublette1, Ainsley Burke1, John J Mann1,4. 1. Division of Molecular Imaging and Neuropathology, Columbia University and New York State Psychiatric Institute, New York, New York. 2. Department of Psychiatry, Psychotherapy, and Psychosomatics, Psychiatric University Hospital Zurich, Zurich, Switzerland. 3. Division of Geriatric Psychiatry, New York State Psychiatric Institute, Columbia University College of Physicians and Surgeons, New York, New York. 4. Department of Radiology, Columbia University, New York, New York.
Abstract
BACKGROUND: Brain mitochondrial dysfunction is implicated in the pathophysiology of mood disorders. Brain cytochrome-c-oxidase (COX) activity is associated with the mitochondrial function. Near-infrared spectroscopy (NIRS) noninvasively measures oxidized COX (oxCOX) and tissue oxygenation index (TOI) reflecting cerebral blood flow and oxygenation. METHODS: oxCOX and TOI were assessed in prefrontal cortex (Fp1/2, Brodmann area 10) in patients in a major depressive episode (N = 13) with major depressive disorder (MDD; N = 7) and bipolar disorder (BD; N = 6) compared with the controls (N = 10). One patient with MDD and all the patients with BD were taking medications. Computational modeling estimated oxCOX and TOI related indices of mitochondrial function and cerebral blood flow, respectively. RESULTS: oxCOX was lower in patients than controls (p = .014) correlating inversely with depression severity (r = -.72; p = .006), driven primarily by lower oxCOX in BD compared with the controls. Computationally modeled mitochondrial parameters of the electron transport chain, such as the nicotinamide adenine dinucleotide ratio (NAD+ /NADH; p = .001) and the proton leak rate across the inner mitochondrial membrane (klk2 ; p = .008), were also lower in patients and correlated inversely with depression severity. No such effects were found for TOI. CONCLUSIONS: In this pilot study, oxCOX and related mitochondrial parameters assessed by NIRS indicate an abnormal cerebral metabolic state in mood disorders proportional to depression severity, potentially providing a biomarker of antidepressant effect. Because the effect was driven by the medicated BD group, findings need to be evaluated in a larger, medication-free population.
BACKGROUND:Brain mitochondrial dysfunction is implicated in the pathophysiology of mood disorders. Brain cytochrome-c-oxidase (COX) activity is associated with the mitochondrial function. Near-infrared spectroscopy (NIRS) noninvasively measures oxidized COX (oxCOX) and tissue oxygenation index (TOI) reflecting cerebral blood flow and oxygenation. METHODS:oxCOX and TOI were assessed in prefrontal cortex (Fp1/2, Brodmann area 10) in patients in a major depressive episode (N = 13) with major depressive disorder (MDD; N = 7) and bipolar disorder (BD; N = 6) compared with the controls (N = 10). One patient with MDD and all the patients with BD were taking medications. Computational modeling estimated oxCOX and TOI related indices of mitochondrial function and cerebral blood flow, respectively. RESULTS:oxCOX was lower in patients than controls (p = .014) correlating inversely with depression severity (r = -.72; p = .006), driven primarily by lower oxCOX in BD compared with the controls. Computationally modeled mitochondrial parameters of the electron transport chain, such as the nicotinamide adenine dinucleotide ratio (NAD+ /NADH; p = .001) and the proton leak rate across the inner mitochondrial membrane (klk2 ; p = .008), were also lower in patients and correlated inversely with depression severity. No such effects were found for TOI. CONCLUSIONS: In this pilot study, oxCOX and related mitochondrial parameters assessed by NIRS indicate an abnormal cerebral metabolic state in mood disorders proportional to depression severity, potentially providing a biomarker of antidepressant effect. Because the effect was driven by the medicated BD group, findings need to be evaluated in a larger, medication-free population.
Authors: Robert D Beech; Lori Lowthert; Janine J Leffert; Portia N Mason; Mary M Taylor; Sheila Umlauf; Aiping Lin; Ji Young Lee; Kathleen Maloney; Anjana Muralidharan; Boris Lorberg; Hongyu Zhao; Samuel S Newton; Shrikant Mane; C Neill Epperson; Rajita Sinha; Hilary Blumberg; Zubin Bhagwagar Journal: Bipolar Disord Date: 2010-12 Impact factor: 6.744
Authors: Nicola Wiles; Laura Thomas; Anna Abel; Maria Barnes; Fran Carroll; Nicola Ridgway; Sofie Sherlock; Nicholas Turner; Katherine Button; Lang'o Odondi; Chris Metcalfe; Amanda Owen-Smith; John Campbell; Anne Garland; Sandra Hollinghurst; Bill Jerrom; David Kessler; Willem Kuyken; Jill Morrison; Katrina Turner; Chris Williams; Tim Peters; Glyn Lewis Journal: Health Technol Assess Date: 2014-05 Impact factor: 4.014
Authors: Johan Fernström; Synthia H Mellon; Marlon A McGill; Martin Picard; Victor I Reus; Christina M Hough; Jue Lin; Elissa S Epel; Owen M Wolkowitz; Daniel Lindqvist Journal: Transl Psychiatry Date: 2021-11-17 Impact factor: 6.222